How to start a ai company?

Start with a clinical problem that has a buyer (not just a cool model)

Most first-time founders start with the algorithm (“we can detect X from Y”). In medtech, you win by starting with a clinical workflow pain that has (1) measurable impact, (2) a clear buyer, and (3) a realistic path through regulation and reimbursement.

Use this quick filter before you write a line of code:

• User: Who touches it daily? (radiologist, ED physician, nurse, lab tech)
• Buyer: Who signs? (hospital department, health system, payer, device OEM)
• Value metric: What moves? (time-to-treatment, readmissions, length of stay, adverse events, throughput)
• Integration surface: Where does it live? (EHR, PACS, bedside device, patient app)
• Regulatory class: Is it clinical decision support (CDS) or Software as a Medical Device (SaMD)?

A practical starting point is a “wedge” use case: narrow scope, high frequency, easy to validate. Examples: triage prioritization, quality control, documentation automation, or risk stratification tied to an existing clinical pathway.

Pick the right product category: CDS vs SaMD (and why it changes everything)

In digital health AI, your regulatory burden depends on what the software claims and how it’s used. Two common buckets:

• Clinical Decision Support (CDS): Software that supports clinicians but allows them to independently review the basis for recommendations. If the clinician can “see the why” and it doesn’t replace judgment, you may reduce regulatory complexity (details vary by use case).
• Software as a Medical Device (SaMD): Software intended to diagnose, treat, cure, mitigate, or prevent disease. Many AI diagnostic tools fall here and often require FDA clearance/approval.

For FDA pathways, early planning matters because it drives your evidence plan and timeline:

• 510(k): You show your device is substantially equivalent to a legally marketed predicate. Common when similar tools exist.
• De Novo: For novel, low-to-moderate risk devices without a predicate. Often used for first-in-category software.
• PMA: For high-risk devices; typically the most demanding evidence burden.

Don’t guess your pathway from vibes. Draft a one-page “intended use” statement and map it to risk. Then sanity-check with a regulatory consultant or experienced advisor before you lock your roadmap.

Data is your moat and your bottleneck: rights, quality, and labeling

AI medtech companies fail more often from data access than from model architecture. You need three things: the right to use data, data that matches your intended use, and labels you can defend.

1) Secure data access the right way

Common sources: hospital partners, device manufacturers, registries, or prospective collection. If you’re working with patient data, expect legal and compliance work (HIPAA in the US, plus institutional policies). You’ll likely need:

• Data Use Agreement (DUA) or equivalent contract defining permitted use, retention, and security
• IRB approval if you’re doing prospective research or certain retrospective studies (varies by institution and design)
• De-identification strategy and security controls aligned with your deployment model

2) Make labeling defensible

Labels are where “research-grade” becomes “product-grade.” Decide whether labels come from:

• Gold standard (e.g., pathology, adjudicated chart review)
• Clinical consensus (multiple clinicians with disagreement resolution)
• Proxy labels (billing codes, problem lists) — faster, but riskier

Write a labeling protocol like a clinical study protocol: inclusion/exclusion criteria, annotation instructions, inter-rater reliability checks, and audit trails.

3) Plan for generalization and bias

Hospitals differ: scanners, protocols, patient mix, documentation habits. Your validation plan should include external sites or at least temporal splits, plus subgroup analysis. Don’t overpromise “works everywhere” unless you can prove it.

Design your evidence plan: clinical validation, not just model metrics

In medtech, AUC alone doesn’t sell. Buyers and regulators care about clinical performance and workflow impact. Build an evidence ladder:

1. Technical validation: data quality, model performance, robustness, failure modes
2. Clinical validation: performance against a clinically meaningful reference standard
3. Clinical utility: does it change decisions or outcomes in real workflow?
4. Economic value: cost savings, revenue capture, throughput, avoided adverse events

For early traction, a retrospective study can be enough to start pilots, but plan ahead for what you’ll need for FDA submission (if applicable) and for hospital value committees. If you’re deploying in a clinical environment, you may need prospective evaluation and careful change management.

Also decide how your model updates will be handled. “Continuous learning” sounds great, but regulated updates require a controlled process. Even pre-FDA, you should implement versioning, monitoring, and rollback.

Go-to-market in hospitals: procurement, integration, and reimbursement

Hospital sales are not like selling SaaS to startups. Expect longer cycles and more stakeholders. Your job is to reduce perceived risk and make adoption easy.

Procurement reality: who says yes?

• Clinical champion: wants it clinically
• IT/security: approves integration, security review, vendor risk management
• Finance/value committee: wants ROI and budget fit
• Compliance/legal: contracts, data handling, BAAs if needed

Design your product to fit their constraints: single sign-on, audit logs, clear uptime commitments, and a deployment model (cloud vs on-prem) that matches their policies.

Reimbursement: CPT codes and who gets paid

Reimbursement can be a growth engine or a dead end. Ask early:

• Is there an existing CPT code that supports billing for the service your AI enables?
• Is the value captured by the hospital, the physician group, or the payer?
• Is your product primarily a cost saver (efficiency, fewer complications) or a revenue enabler (new billable services)?

If reimbursement is unclear, you can still win via operational ROI (e.g., throughput, reduced length of stay), but you must quantify it with credible assumptions and pilot data.

Pricing: tie it to value and workflow

Common pricing models in medtech AI include per-study, per-user, per-site, or enterprise licenses. Choose based on where value is created and how usage is measured. Avoid pricing that requires heroic tracking by the customer.

What to do next

1. Write a one-page “Problem → User → Buyer → Metric” brief and validate it with 10 clinician interviews and 5 admin/IT interviews.
2. Draft your intended use statement and do a first-pass mapping to 510(k) vs De Novo vs PMA (then confirm with a regulatory expert).
3. Secure a data path: identify one hospital partner and outline DUA/IRB needs; define your labeling protocol and reference standard.
4. Plan a pilot that proves ROI: pick 1–2 measurable endpoints (time saved, reduced callbacks, improved triage) and design the workflow integration.
5. Build your commercialization checklist: security review items, integration requirements (EHR/PACS), and a simple pricing hypothesis.

If you want templates for validation planning, competitive positioning, and early pricing, explore StartupLaby’s tools below.